Inovio Receives FDA Accelerated Approval for VOCERYQ to Treat Recurrent Respiratory Papillomatosis

Inovio Pharmaceuticals said the FDA granted accelerated approval to VOCERYQ, formerly INO-3107, a plasmid DNA-based immunotherapy for adults with recurrent respiratory papillomatosis that targets HPV-6 and HPV-11 and is intended to reduce surgery frequency. It is the first plasmid DNA-based immunotherapy approved in the United States and, according to Inovio, validates its CELLECTRA delivery platform. The company expects to begin taking orders and shipping in about 60 days, with a full commercial launch anticipated in the first quarter of 2027. Approval requires Inovio to conduct a post-marketing confirmatory study.